Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon(Brigham and Women's Hospital), Gordon J. Freeman(Dana-Farber Cancer Institute)
Cited by 434
Related Papers
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.4k
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8<sup>+</sup> T cell activation and cytolysis
|European Journal of Immunology|2003|482
Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
|The Journal of Experimental Medicine|1993|353
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
|The Journal of Experimental Medicine|2014|322
Cloning of BY55, a Novel Ig Superfamily Member Expressed on NK Cells, CTL, and Intestinal Intraepithelial Lymphocytes
|The Journal of Immunology|1998|146